MIND diet for adults with multiple sclerosis
Randomized Controlled Trial of MIND Diet for Neuroprotection and Symptom Management in MS
NA · Icahn School of Medicine at Mount Sinai · NCT06992115
This program will test whether following the MIND diet for one year helps brain health and reduces MS symptoms in adults with multiple sclerosis.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Icahn School of Medicine at Mount Sinai (other) |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT06992115 on ClinicalTrials.gov |
What this trial studies
This randomized, stratified early phase II trial assigns adults with MS to either a one-year MIND dietary intervention with dietitian-led education and virtual support groups, or to a control arm that continues their usual diet and receives MS-related education unrelated to diet. Participants complete baseline, 6-month, and 12-month in-person visits with functional and cognitive testing, provide blood and stool samples, and complete online questionnaires. The intervention arm receives intensive virtual small-group meetings weekly for the first month and then monthly through month 12 to support MIND diet adherence. Randomization is stratified by MS phenotype and treatment type to balance groups.
Who should consider this trial
Good fit: Adults aged 18–70 with a diagnosis of multiple sclerosis, a baseline MIND diet score of 8 or less, and who are not pregnant are ideal candidates.
Not a fit: People with additional neurodegenerative or serious medical conditions, those planning pregnancy, or individuals already following a MIND-like diet (score above 8) may be unlikely to gain benefit from this trial.
Why it matters
Potential benefit: If successful, the MIND diet could offer a low-risk way to support brain health and reduce symptoms for people with MS.
How similar studies have performed: MIND and Mediterranean-style diets have shown cognitive and neuroprotective signals in aging and dementia research, but randomized evidence in MS is limited, making this a relatively novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ages 18-70 years, inclusive * MS diagnosis, on any treatment (including no treatment) * MIND diet score of ≤8 at baseline * NfL parameters determined by age Exclusion Criteria: * Diagnosis of an additional neurodegenerative disease (e.g. Alzheimer's) or other serious neurological condition (e.g. stroke) * Current serious medical condition that could impact the ability to participate or influence study results (e.g. cancer, HIV) * Pregnancy/planning during study period
Where this trial is running
New York, New York
- Mount Sinai Hospital — New York, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Ilana B Katz Sand, MD — Icahn School of Medicine at Mount Sinai
- Study coordinator: Claire E Wigley, Bsc, BSPH
- Email: claire.wigley@mssm.edu
- Phone: (212) 241-3759
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Sclerosis, Diet